Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of May. Click the trial title to get more details.
The following alert was issued on May 18:
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A & B)
Status: Enrolling
Description: This first-in-human study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 50 to 90%
Number of Visits: 21
Length of Participation: 12 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03375047